Eurofins Discovery, provider of services and products to the drug discovery industry, and PharmaResources, a contract research organization (CRO) based in Shanghai, China, specializing in small molecule drug R&D and manufacture, announced a commercial cooperation to provide PharmaResources’ customers with expedited access to Eurofins Discovery’s pharmacology and ADMET portfolio to accelerate their client’s drug discovery timelines. 
 
PharmaResources’ 300 chemists and 30+ drug discovery programs will be able to provide their customers with in vitro pharmacology and ADME assessments, which enables earlier and faster access to safety and efficacy data through a single integrated platform. The cooperation improves R&D efficiency as medicinal chemists at PharmaResources will have rapid access to pharmacology and ADMET data through this cooperation with Eurofins Discovery. 
 
“Our commitment to reducing the time and cost of drug discovery to worldwide pharmaceutical clients, and especially those in China, is enriched through Eurofins Discovery’s biology platforms with the discovery chemistry platform of PharmaResources,” said Christina Shasserre, senior vice president, Eurofins Discovery. “PharmaResources is an internationally recognized leader in medicinal and process chemistry with outstanding track records in early drug discovery and shares our vision of reducing the time it takes to generate safe and efficacious therapies for drug developers.”
 
Ping Chen, chief executive officer, PharmaResources, said, “Eurofins Discovery provides high quality expertise in discovery biology with a broad spectrum of biology assays and ADMET, with a robust in vitropharmacology platform. Through this cooperation, we are combining the strengths of both companies and are establishing a small molecule drug discovery service platform in a virtual integrated fashion. Several on-going discovery programs have already shown the benefit from this cooperation and we believe that this platform will provide rapid, high quality services to clients and facilitate their research on novel small molecule drugs in a synergistic way.”